Section Reviews Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis: Novel allergy therapeutics

References

• NOON L: Prophylactic inoculation against hay fever.Lancet (1911) L1572.
   Google Scholar
• COMMITTEE ON SAFETY OF DRUGS: Committee onSafety of Drugs Update. Desensitising vaccines. Br. Med. J. (1986) 293:948.
   PubMedGoogle Scholar
• EISER N: Desensitisation today. A specialist procedure with few indications. Br. Med. J. (1990) 300:1412–1413.
   Google Scholar
• ROCKLIN RE, SHEFFER AL, GREINEDER DK, MELMON KK: Generation of antigen specific suppressor cells during allergy desensitisation. New Engl. J. Med. (1980) 302:1213–1217.
   PubMed Web of Science ®Google Scholar
• PRODUCT NEWS: SCRIP No. 1905 (1994) March 15th P. 27; see also SCRIP No. 1953 (1994) Aug. 30th, P. 15.
   Google Scholar
• HOLT PG: A potential vaccine strategy for asthma and allied atopic diseases during early childhood. Lancet (1994) 344:456–458.
   PubMed Web of Science ®Google Scholar
• DAVIS FM GOSSETT LA, CHANG TW: An epitope on membrane bound but not secreted IgE: implications in isotype-specific regulation. Biotechnology (1991) 9:53–56.
   PubMedGoogle Scholar
• SCRIP No. 1771 (1992) p. 26; No. 1867 (1993) p. 11.
   Google Scholar
• LOVELESS HN: Development of an anti-IgE monoclonal antibody for the prevention and treatment of asthma. Cambridge Healthtech. Institute Symposium. New asthma therapeutics: Shijtingfrorm symptoms to causes. Dec 1–2,1994. New Orleans. Abstract.
   Google Scholar
• SHAKIB F, SMITH GJ: In vitro basophil histamine releas-ing activity of circulating Ig64 and Ig64 auto-anti IgE antibodies from asthma patients, and the demonstra-tion that anti-IgE modulates allergen-induced basophil activation. Clin. Exp. Allergy (1994) 24:270–275.
   PubMed Web of Science ®Google Scholar
• MACHIELS JJ, SOMVILLE MA, LEBRUN PM, LEBECQUE SJ, ACQUEMIN MC, SAINT-REMY J-MR: Allergic bronchial asthma due to Dermatopbagoides pteronyssinus hy-persensitivity can be efficiently treated by innoculation of allergen-antibody complexes. J. CIO:. Invest. (1990) 85:1024–1035.
   PubMedGoogle Scholar
• GEHA RS, COMUNALE M: Regulation of immunogkibulin E antibody synthesis in man by anti-idiotopic antibod-ies. J. Ctn. Invest. (1983) 71:46–54.
   PubMed Web of Science ®Google Scholar
• HASSNER A, SAXON A: Isotype-specific T cells for IgE synthesis activated by IgE-anti IgE immune complexes. J. Immunol. (1984) 132:2844–2849.
   PubMed Web of Science ®Google Scholar
• PENE J, SOUSSET F, ET AL.: IgE production by normal human lymphocytes as induced by interleukin 4 and suppressed by interferon a and prostaglandin E2. Proc. Natl. Acad. Sci. USA (1988) 85:6880.
   Google Scholar
• FINICELMAN FD, KATONA IM, URBAN JF, SNAPPER CM, OHARA J, PAUL WE: Suppression of in vivo polyclonal IgE responses by monoclonal antibody to the lymphok-ine B-cell stimulatory factor 1. Proc. Natl. Acad. Sci. USA (1986) 83:9675–9678.
   PubMed Web of Science ®Google Scholar
• SPIEGELBERG H: Inhibition of human IgE formation in Hu-PBL-SCID mice. Proc. IBC. Conference. New Approaches to the Treatment of Allergic Diseases and Asthma. (1994) November. Cambridge, Massachusetts. Abstract.
   Google Scholar
• FLORES-ROMO L, SHIELDS J, HUMBERT Y, GRABER P, AUBRY J-P, GAUCHAT J-F, AYALA G, ALLET B, CHAVEZ M, BAZIN H, CAPRON M, BONNEFOY J-Y: Inhibition of an in vivo antigen-specific IgE response by antibodies to CD23. Science (1993) 261:1038–1041.
   PubMed Web of Science ®Google Scholar
• STANWORTH OR, HUMPHREY JH, BENNICH H, JOHANS-SON SGO: Specific inhibition of the Prausnitz-Kfistner reaction by an atypical human myeloma protein. Lancet (1967) 1:330–332.
   Google Scholar
• STANWORTH DR, HUMPHREY JH, BENNICH H, JOHANS-SON SGO: Inhibition of Prausnitz-Kiistner reaction by proteolytic human myeloma protein of immunoglobu-lin class E. Lancet (1968) 117–18.
   PubMedGoogle Scholar
• STANWORTH OR: The experimental inhibition of reagin-mediated reactions. Clinical Allergy(1971) 1:25–35.
   PubMedGoogle Scholar
• JARRETT E, MACKENZIE S, BENNICH H: Parasite induced'non-specific' IgE does not protect against allergic reac-tions. Nature (1980) 283:302–304.
   PubMed Web of Science ®Google Scholar
• HAMBURGER RN: Peptide inhibition of the Prausnitz-Kiistner reaction. Science (1975) 189:389.
   PubMed Web of Science ®Google Scholar
• BENNICH H, RAGNARSSON U, JOHANSSON SGO, ISHISAKA K, ISHISAKA T, LEVY DA, LICHENSTEIN GM: Failure of the putative IgE pentapeptide to compete with IgE for receptors on basophils and mast cells. Int. Arch. Allergy Appl. Immun. (1977) 53: 459.
   PubMedGoogle Scholar
• STANWORTH OR, KINGS M, ROY PD, MORGAN DH: Inves-tigation of the reputed inhibition of the Prausnitz-Kiist-ner reaction by the pentapeptide Asp-Ser-Asp-Pro-Arg. Int. Arch. Allergy Appl. Immun. (1978) 56:409–415.
   PubMedGoogle Scholar
• KALPAXIS JG, THAYER TO: Double blind trial of pen-tigetide ophthahnic solution, 0.5%, compared with cro-molyn sodium, 4% ophthalmic solution for allergic conjunctivitis. Annals Allergy (1991) 66:393–398.
   Google Scholar
• MANSMANN HC, ROSEN J, ZIERING R, HAMPEL F, RATHER P, FINDLAY S, KNIKER W, HADDAD Z, DAIGLE A: Pen-tigetkle nasal solution: a multicenter study evaluating efficacy and safety in patients with seasonal allergic rhinitis. Annals Allergy (1991) 67:409–415.
   PubMedGoogle Scholar
• STANWORTH DR: Immunochemistry of IgE. Proc. Royal Soc. Medicine (1969) 62:971.
   PubMedGoogle Scholar
• STANWORTH DR: Immunoglobulin E (Reagin) and al-lergy. Nature (1971) 233:310–316.
   PubMed Web of Science ®Google Scholar
• JASANI B, STANWORTH OR: Studies on the mast cell triggering action of certain artificial histamine libera-tors. Int. Arch. Allergy (1973) 45:74–81.
   Web of Science ®Google Scholar
• BENNICH H, BAHR-LINSTROM H VON: Structure of im-munoglobulin E. Prog. Immun. 11(1978) 1: 49.
   Google Scholar
• STANWORTH OR, KING SM, ROY PD, MORAN JM, MORAN DM: Synthetic peptides comprising a sequence of hu-man ittununoglobulin E heavy chain capable of releas-ing histamine. Biochem. J. (1979) 180:665.
   PubMed Web of Science ®Google Scholar
• STANWORTH OR, COLEMAN JW, KHAN Z: Essential structural requirements for triggering of mast cells by a synthetic peptide comprising a sequence in the CM. Molec. Immunol. (1984) 21:243–247.
   PubMed Web of Science ®Google Scholar
• STANWORTH OR, JONES VM, LEWIN IV, NAYYAR S: Allergy treatment with a peptide vaccine. Lancet (1990) 336:1279–1281.
   PubMed Web of Science ®Google Scholar
• STANWORTH OR: Immunotherapy of atopic diseases with peptide vaccines. Advances in Tumour Immunology and Allergic Disorders (1992) 18:305–317.
   Google Scholar
• CAPRON A, DESSAINT JP: Immunologic aspects of schis-tosomiasis. Ann. Rev. Med. (1992) 43:209–218.
   PubMedGoogle Scholar
• BURT S, STANWORTH OR: Inhibition of binding of ratIgE to rat mast cells by synthetic IgE peptides. Euro. J. Immunol. (1987) 17:437–440.
   PubMed Web of Science ®Google Scholar
• SPIEGELBERG HL: Does IgE receptor blockade have achance for treatment of allergy? Proc. 13' Mt. Congr. Allergology C1M. Immunol. Montreux 1988. Progress in Al-lergy & din. Immunol. Pichler WJ et al. (Eds.). Hogrefe & Huber (1989):114–116.
   Google Scholar